SCHEMBL4132561

SCHEMBL4132561

CC1(c2ccnc3ccccc23)CCCCc2c(N3CCNCC3)nc(N)nc21

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 12/20 0.43
HRH3 Q9Y5N1 5/20 0.43
ADRB2 P07550 1/20 0.42
NCF1 P14598 1/20 0.42
KCNH2 Q12809 1/20 0.40
HTR2C P28335 1/20 0.39
HTR3E A5X5Y0 1/20 0.37
HTR3B O95264 1/20 0.37
HTR3A P46098 1/20 0.37
HTR3D Q70Z44 1/20 0.37
HTR3C Q8WXA8 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
TSHR P16473 1/20 0.37
CLK4 Q9HAZ1 1/20 0.37
TGFBR1 P36897 1/20 0.36
ACVR1 Q04771 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4129610 0.82 HRH4 (0.54) HRH4HRH3KCNH2
SCHEMBL4116716 0.82 HTR2C (0.49) HRH4HRH3HTR2CCYP1A2CYP3A4
SCHEMBL4122912 0.82 HRH4 (0.47) HRH4HRH3KCNH2HTR2C
SCHEMBL4128029 0.81 HRH4 (0.49) HRH4HRH3KCNH2CYP1A2CYP3A4
SCHEMBL4134476 0.79 HRH4 (0.55) HRH4HRH3KCNH2
SCHEMBL4115636 0.79 HRH4 (0.47) HRH4HRH3HTR2C
SCHEMBL4135282 0.79 HRH4 (0.45) HRH4HRH3KCNH2CYP1A2CYP3A4
SCHEMBL4124018 0.78 HRH4 (0.49) HRH4HRH3KCNH2HTR3EHTR3B
SCHEMBL4125137 0.76 HRH4 (0.51) HRH4HRH3KCNH2
SCHEMBL4124051 0.75 HRH4 (0.44) HRH4HRH3HTR3ACYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436005-B2 Macrocyclic pyrimidine derivatives ABBOTT LABORATORIES (US) 2013-05-07 US disclosed
US-8436005-B2 Macrocyclic pyrimidine derivatives ABBOTT LABORATORIES (US) 2013-05-07 US disclosed
WO-2009123967-A1 5,6,7,8-TETRAHYDROQUINAZOLIN-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H4 RECEPTOR MODULATORS FOR THE TREATMENT OF ASTHMA ABBOTT LABORATORIES (US) 2009-10-08 WO disclosed
US-20090253678-A1 MACROCYCLIC PYRIMIDINE DERIVATIVES ABBOTT LABORATORIES (US) 2009-10-08 US disclosed
US-20090253678-A1 MACROCYCLIC PYRIMIDINE DERIVATIVES ABBOTT LABORATORIES (US) 2009-10-08 US disclosed
US-20090253678-A1 MACROCYCLIC PYRIMIDINE DERIVATIVES ABBOTT LABORATORIES (US) 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253678-A1 MACROCYCLIC PYRIMIDINE DERIVATIVES DPYD, TYMS, TYMP HRH4 3370/4885HRH3 3555/4885ADRB2 4521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.